Regeneron Pharmaceuticals
REGN
624 hedge funds and large institutions have $25B invested in Regeneron Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 240 increasing their positions, 211 reducing their positions, and 59 closing their positions.
19% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 59
14% more repeat investments, than reductions
Existing positions increased: 240 | Existing positions reduced: 211
1% more funds holding
Funds holding: 619 → 624 (+5)
0% more capital invested
Capital invested by funds: $24.9B → $25B (+$107M)
0.19% more ownership
Funds ownership: 68.47% → 68.66% (+0.19%)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
37% less call options, than puts
Call options by funds: $566M | Put options by funds: $893M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
+$453M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$426M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$167M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$152M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$63.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$280M |
| 2 |
O
OrbiMed
New York
|
-$185M |
| 3 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$172M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$112M |
| 5 |
D.E. Shaw & Co
New York
|
-$104M |
REGN Hedge Fund Activity: Q2 2018 in Review
624 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2018, worth a combined $25B — up 0.43% from $24.9B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new REGN positions and 59 closed out — a net gain of 11 holders — while 240 added to existing stakes and 211 trimmed.
The largest buyer was Harris Associates, adding an estimated $453M. The largest seller was Fidelity Investments, cutting an estimated $280M.
- 624 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2018, up from 619 in Q1 2018.
- Funds reported $25B of Regeneron Pharmaceuticals stock for Q2 2018, up 0.43% quarter-over-quarter.
- 70 funds opened new Regeneron Pharmaceuticals positions in Q2 2018 and 59 closed out, a net change of +11 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2018 was Harris Associates, an estimated $453M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2018 was Fidelity Investments, an estimated $280M sold.
Based on aggregated 13F filings for Q2 2018.